Abbott ceo says "it's clear that the need for testing is large and it isn't going away" - conf call

Abbott ceo says at the end of june, procedure volumes rebounded to 90% of pre-crisis levels on average in u.s. - conf call.abbott ceo says will launch freestyle libre 2 in the next few weeks at the same price as the current available freestyle libre 14-day system - conf call.abbott ceo says testing volumes in diagnostic business excluding covid-19 tests, rebounded to about 90% of pre-covid levels by end of q2 - conf call.abbott in addition to molecular testing, anticipate increased demand for other types of tests, including both antigen and antibody - conf call.abbott ceo says " it's clear that the need for testing is large and it isn't going away" - conf call.abbott ceo says as vaccines become available, anticipate continued surveillance testing to monitor and assess for both natural and vaccine-related immune response - conf call.abbott ceo says the capacity we are building for covid-19 testing is not only for a high demand during the next 12-24 months - conf call.
ABT Ratings Summary
ABT Quant Ranking